Nuvation Bio Inc.
For the period ended Sep 30, 2025. Filed Nov 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 3, 2025
NUVB$4.35+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share data)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $98,897 | $35,723 |
| Accounts receivable, net of allowance for credit loss of $nil | 8,323 | 12,722 |
| Inventory | 5,710 | — |
| Prepaid expenses and other current assets | 8,925 | 7,271 |
| Marketable securities | 450,148 | 466,969 |
| Interest receivable on marketable securities | 5,527 | 3,570 |
| Total current assets | 577,530 | 526,255 |
| Property and equipment, net of accumulated depreciation of $1,110 and $874, respectively | 560 | 586 |
| Intangible assets, net of accumulated amortization of $1,390 and $448, respectively | 11,680 | 4,622 |
| Operating lease right-of-use assets | 4,329 | 2,402 |
| Other non-current assets | 7,462 | 6,761 |
| Total assets | $601,561 | $540,626 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $15,360 | $6,348 |
| Current operating lease liabilities | 1,871 | 1,663 |
| Contract liabilities, current portion | 6,721 | 11,117 |
| Liability related to revenue interest financing agreement | 5,982 | — |
| Short-term borrowings | 5,618 | 6,283 |
| Accrued expenses | 32,579 | 32,833 |
| Total current liabilities | 68,131 | 58,244 |
| Warrant liability | 1,738 | 2,053 |
| Contract liabilities, net of current portion | 11,130 | 15,572 |
| Non-current operating lease liabilities | 2,970 | 969 |
| Non-current liability related to revenue interest financing agreement, net of current portion and deferred financing costs of $4,450 and $0 as of September 30, 2025 and December 31, 2024 | 144,621 | — |
| Long-term borrowings, net of current portion and deferred financing costs of $3,161 and $0 as of September 30, 2025 and December 31, 2024 | 47,089 | — |
| Total liabilities | 275,679 | 76,838 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000, Class B 60,000,000) shares authorized as of September 30, 2025 and December 31, 2024 respectively, 342,756,387 (Class A 341,756,387, Class B 1,000,000) and 337,837,872 (Class A 336,837,872, Class B 1,000,000) shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 1,404,799 | 1,373,958 |
| Accumulated deficit | (1,078,778) | (910,743) |
| Accumulated other comprehensive (loss) income | (139) | 573 |
| Total stockholders’ equity | 325,882 | 463,788 |
| Total liabilities and stockholders’ equity | $601,561 | $540,626 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.